Literature DB >> 12959182

Pathology of ovarian carcinoma.

Jeffrey D Seidman1, Robert J Kurman.   

Abstract

Serous carcinoma is the most common type of ovarian cancer and usually is associated with peritoneal metastases and poor survival except for meticulously staged patients with tumors confined to the ovaries. Endometrioid and clear cell carcinomas account for most nonserous carcinomas and more often present with low-stage disease; survival for the various cell types is similar when stratified by stage. Borderline ovarian tumors can be subdivided into benign and malignant neoplasms, and in the view of some experts, this renders the borderline category obsolete. Women with typical serous borderline tumors (atypical proliferative serous tumors) constitute most of these patients and have virtually 100% survival, unless invasive peritoneal implants are present. Micropapillary serous carcinomas (a less common variant, also called serous borderline tumor with a micropapillary pattern) and tumors with invasive implants behave similar to low-grade invasive carcinomas.

Entities:  

Mesh:

Year:  2003        PMID: 12959182     DOI: 10.1016/s0889-8588(03)00061-3

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  19 in total

1.  A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4317 women diagnosed in Denmark 1978-2006.

Authors:  Charlotte Gerd Hannibal; Russell Vang; Jette Junge; Anette Kjaerbye-Thygesen; Robert J Kurman; Susanne K Kjaer
Journal:  Gynecol Oncol       Date:  2012-02-24       Impact factor: 5.482

2.  Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment.

Authors:  Ibrahim Yalcin; Mehmet Mutlu Meydanli; Ahmet Taner Turan; Salih Taskin; Mustafa Erkan Sari; Tayfun Gungor; Ozgur Akbayir; Ali Ayhan
Journal:  Int J Clin Oncol       Date:  2017-11-16       Impact factor: 3.402

Review 3.  Breast and ovarian cancers: a survey and possible roles for the cell surface heparan sulfate proteoglycans.

Authors:  Atsuko Yoneda; Maria E Lendorf; John R Couchman; Hinke A B Multhaupt
Journal:  J Histochem Cytochem       Date:  2012-01       Impact factor: 2.479

4.  Tubal Ligation Induces Quiescence in the Epithelia of the Fallopian Tube Fimbria.

Authors:  Ekaterina Tiourin; Victor S Velasco; Miguel A Rosales; Peggy S Sullivan; Deanna M Janzen; Sanaz Memarzadeh
Journal:  Reprod Sci       Date:  2015-03-02       Impact factor: 3.060

5.  Myosin II co-chaperone general cell UNC-45 overexpression is associated with ovarian cancer, rapid proliferation, and motility.

Authors:  Martina Bazzaro; Antonio Santillan; Zhenhua Lin; Taylor Tang; Michael K Lee; Robert E Bristow; Ie-Ming Shih; Richard B S Roden
Journal:  Am J Pathol       Date:  2007-09-14       Impact factor: 4.307

Review 6.  Genomic analysis of epithelial ovarian cancer.

Authors:  John Farley; Laurent L Ozbun; Michael J Birrer
Journal:  Cell Res       Date:  2008-05       Impact factor: 25.617

7.  Morphological and molecular basis of ovarian serous carcinoma.

Authors:  Daniel G Rosen; Zhihong Zhang; Weiwei Shan; Jinsong Liu
Journal:  J Biomed Res       Date:  2010-07

8.  Emerging role of microRNAs in diagnosis and treatment of various diseases including ovarian cancer.

Authors:  Parag P Shah; Lauren E Hutchinson; Sham S Kakar
Journal:  J Ovarian Res       Date:  2009-08-27       Impact factor: 4.234

9.  Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis.

Authors:  Mandi M Murph; Wenbin Liu; Shuangxing Yu; Yiling Lu; Hassan Hall; Bryan T Hennessy; John Lahad; Marci Schaner; Aslaug Helland; Gunnar Kristensen; Anne-Lise Børresen-Dale; Gordon B Mills
Journal:  PLoS One       Date:  2009-05-15       Impact factor: 3.240

10.  Supra-clavicular lymph node metastatic spread in patients with ovarian cancer disclosed at 18F-FDG-PET/CT: an unusual finding.

Authors:  S Fanti; C Nanni; P Castellucci; M Farsad; L Rampin; M D Gross; G Mariani; D Rubello
Journal:  Cancer Imaging       Date:  2006-03-23       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.